Horne Hisani N, Beena Devi C R, Sung Hyuna, Tang Tieng Swee, Rosenberg Philip S, Hewitt Stephen M, Sherman Mark E, Anderson William F, Yang Xiaohong R
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
Breast Cancer Res Treat. 2015 Jan;149(1):285-91. doi: 10.1007/s10549-014-3243-9. Epub 2014 Dec 24.
Hormone receptor (HR) negative breast cancers are relatively more common in low-risk than high-risk countries and/or populations. However, the absolute variations between these different populations are not well established given the limited number of cancer registries with incidence rate data by breast cancer subtype. We, therefore, used two unique population-based resources with molecular data to compare incidence rates for the 'intrinsic' breast cancer subtypes between a low-risk Asian population in Malaysia and high-risk non-Hispanic white population in the National Cancer Institute's surveillance, epidemiology, and end results 18 registries database (SEER 18). The intrinsic breast cancer subtypes were recapitulated with the joint expression of the HRs (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor-2 (HER2). Invasive breast cancer incidence rates overall were fivefold greater in SEER 18 than in Malaysia. The majority of breast cancers were HR-positive in SEER 18 and HR-negative in Malaysia. Notwithstanding the greater relative distribution for HR-negative cancers in Malaysia, there was a greater absolute risk for all subtypes in SEER 18; incidence rates were nearly 7-fold higher for HR-positive and 2-fold higher for HR-negative cancers in SEER 18. Despite the well-established relative breast cancer differences between low-risk and high-risk countries and/or populations, there was a greater absolute risk for HR-positive and HR-negative subtypes in the US than Malaysia. Additional analytical studies are sorely needed to determine the factors responsible for the elevated risk of all subtypes of breast cancer in high-risk countries like the United States.
激素受体(HR)阴性乳腺癌在低风险国家和/或人群中相对比高风险国家和/或人群更为常见。然而,鉴于按乳腺癌亚型提供发病率数据的癌症登记处数量有限,这些不同人群之间的绝对差异尚未明确确立。因此,我们使用了两个独特的基于人群的分子数据资源,来比较马来西亚低风险亚洲人群与美国国立癌症研究所监测、流行病学和最终结果18登记数据库(SEER 18)中高风险非西班牙裔白人人群之间“内在”乳腺癌亚型的发病率。通过HR(雌激素受体和孕激素受体)与人表皮生长因子受体2(HER2)的联合表达来概括内在乳腺癌亚型。总体而言,SEER 18中的浸润性乳腺癌发病率比马来西亚高五倍。在SEER 18中,大多数乳腺癌为HR阳性,而在马来西亚则为HR阴性。尽管马来西亚HR阴性癌症的相对分布更大,但SEER 18中所有亚型的绝对风险更高;SEER 18中HR阳性癌症的发病率高出近7倍,HR阴性癌症高出2倍。尽管低风险和高风险国家和/或人群之间乳腺癌的相对差异已得到充分证实,但美国HR阳性和HR阴性亚型的绝对风险比马来西亚更高。迫切需要进行更多的分析研究,以确定像美国这样的高风险国家中所有乳腺癌亚型风险升高的原因。